Other Events ·
Incannex Healthcare Inc. announced the dosing of the first patient in its DReAMzz Phase 2 dose-optimization study for…
IXHLIncannex Healthcare Inc.
Incannex Healthcare Inc. announced the dosing of the first patient in its DReAMzz Phase 2 dose-optimization study for IHL-42X, an oral fixed-dose combination drug candidate for obstructive sleep apnea. This milestone follows positive results from the prior Phase 2 RePOSA study, which demonstrated statistically significant reductions in the apnea-hypopnea index (AHI) of up to 83% and established a strong safety profile. The company also highlighted its FDA Fast Track designation for IHL-42X, which facilitates expedited review due to unmet medical needs. The DReAMzz study involves 14 clinical sites in the United States and aims to optimize dosing to support future Phase 3 development. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.